BIOCRYST PHARMACEUTICALS, INC. Inventory Write-down
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Inventory Write-down of $583.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-06-30 was $509.00K, a 37.70% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-03-31 was $74.00K, a 64.59% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-12-31 was -$71.00K.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-09-30 was $30.00K, a 97.79% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for fiscal 2025 was $985.00K, a 27.04% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for fiscal 2024 was $1.35M, a 219.91% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for fiscal 2023 was $422.00K, a 54.72% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. inventory write-down for fiscal 2022 was $932.00K.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $509.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $583.00K 10-Q · filed 2026-08-05 | $512.00K derived: sum of 3 quarters · filed 2026-08-05 | $542.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $74.00K 10-Q · filed 2026-05-06 | $3.00K derived: sum of 2 quarters · filed 2026-05-06 | $33.00K derived: sum of 3 quarters · filed 2026-05-06 | $850.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$41.00K derived: sum of 2 quarters · filed 2026-02-26 | $776.00K derived: sum of 3 quarters · filed 2026-08-05 | $985.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $847.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.06M 10-Q · filed 2025-11-04 | $1.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $817.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.03M 10-Q · filed 2026-08-05 | $1.01M derived: sum of 3 quarters · filed 2026-08-05 | $2.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $209.00K 10-Q · filed 2026-05-06 | $198.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.56M derived: sum of 3 quarters · filed 2026-05-06 | $1.56M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.35M derived: sum of 2 quarters · filed 2026-02-26 | $1.35M derived: sum of 3 quarters · filed 2026-02-26 | $1.35M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.36M derived: sum of 2 quarters · filed 2025-11-04 | $1.36M 10-Q · filed 2025-11-04 | $1.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.00K 10-Q · filed 2025-08-05 | $187.00K derived: sum of 3 quarters · filed 2026-02-26 | $185.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $186.00K derived: sum of 2 quarters · filed 2026-02-26 | $184.00K derived: sum of 3 quarters · filed 2026-02-26 | $186.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $184.00K derived: sum of 2 quarters · filed 2026-02-26 | $186.00K derived: sum of 3 quarters · filed 2026-02-26 | $422.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $236.00K 10-Q · filed 2024-11-05 | $1.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $238.00K 10-Q · filed 2024-08-06 | $1.17M derived: sum of 3 quarters · filed 2025-02-25 | $1.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $236.00K 10-Q · filed 2024-05-07 | $1.17M derived: sum of 2 quarters · filed 2025-02-25 | $1.17M derived: sum of 3 quarters · filed 2025-02-25 | $1.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $932.00K derived: sum of 2 quarters · filed 2025-02-25 | $932.00K derived: sum of 3 quarters · filed 2025-02-25 | $932.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |